Key facts
- Ignota Labs’s last known valuation is $20.1M (Feb 2025).
- It has raised $7.6M; the latest was Seed Round ($6.8M) in Feb 2025.
- Notable investors include Gaingels, Loyal VC, Sustainable Ventures, AIX Ventures, Modi Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Ignota Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Ignota Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ignota Labs
Developer of medical technology designed to optimize the drug discovery process, eliminating compounds harmful to the environment and minimizing waste. The company's platform uses artificial intelligence algorithms to predict toxic endpoints, earlier in the drug discovery process, enabling the pharmaceutical industry to be more sustainable by reducing environmental damage and improving drug safety.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2021
- Employees
- 9
- Website
- ignotalabs.ai/
- Ownership
- Privately Held (backing)
Ignota Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ignota Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ignota Labs in its N-PORT filings yet. We sweep new filings monthly.